Part 1

Our value-creation model

Our roadmap “Conquest 2025”

1 . Innovate to care for 200 million patients and consumers.

2. Establish our scientific and medical leadership.

3. Optimize our operational excellence.

4. Preserve our ecosystems.

5. Build our collective future.

Our Mission

Constantly innovate to take care.

Our therapeutic fields

Oncology, Dermatology, Rare diseases, Chronic diseases, Smoking cessation, Consumer health- care, Natural health, Oral health.

Our holistic approach to healthcare

Prevent, Treat, Provide support for pathologies and their side effects

Our brands

Dermo-cosmetics: Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Darrow, Dexeryl, MÊME

Oral health: Elgydium, Arthrodont, Eludril, Inava

Our ultimate goal Contribute to the common good

All profits not reinvested in the company are channeled back into the Fondation Pierre Fabre, a government-recognized, public-interest foundation since 1999, which works to improve access to quality healthcare in the Global South.

Our company purpose

Every time we care for a single person, we make the whole world better.

A global company

→ 2nd largest global dermo-cosmetics company.
→ 70% of total revenue from international sales.
→ 90% of oncology revenue from international sales.
→ 43 subsidiaries on five continents.
Products distributed in 120 countries.

Financial resources

→ Net sales: €2.83 billion (+6% on a constant exchange rate basis).
→ Operating profit: +12% compared to 2022.
100% of profits reinvested in the company's development*.
→ €200 million financed by take-up of equity funding for the acquisition of new molecules.

*Except for dividends paid out to the Pierre Fabre Foundation

Investments

Investing in R&D innovation

→ 500 employees.
→ 42% of the budget dedicated to skin health (dermatology, dermo-cosmetics).
→ 2nd most innovative laboratory in France in the field of oncology, based on the number of patents filed*.
→ 52% of the budget dedicated to the fight against cancer.
→ 5 innovation centers, with a main research unit based on the Toulouse Oncopole campus.

*2002-2021 (source: INPI)

Investing in French production

→ 95% of the products marketed by our international brands are made in France by 2,000 employees at 6 industrial sites.
→ 2 major active ingredients used in oncology are currently being relocated to Gaillac (with backing from France Relance 2030).
→ 98% of our drugs are not sourced exclusively in Asia.
→ €250 million industrial investments planned over the 2023-2027 period.

Investing in employee training

→ 5,900 employees attended a training session French data.
→500 work placement students and trainees hosted in France.
→4,800 employees took part in the Safety at Work Week.
→11,000 people attended 43 conferences and workshops held during “Skill Week” focused on Data and AI.
→10,000 open-access training modules available.

Value creation and sharing

Therapeutic progress

→ The Prix Galien award for advanced therapy medicinal products was awarded in France to EBVALLO®, the first allogeneic cell therapy marketed in Europe.
→ 9 clinical trials in progress over 19 countries.
→ 32 real-world evidence studies in progress.
→ 50,000 patients enrolled in the ALL study on the impact of dermatological pathologies on quality of life.

Medical knowledge

→ 181 scientific publications aimed at improving medical knowledge.
→ 30,000 healthcare professionals subscribed to Dermaweb, the leading international website for the exchange of information between dermatologists.
→ 38,000 physicians signed up to the Dermatoscopy application, providing assistance for screening and monitoring skin disorders.
→ 3,600 pharmacists connected to OncoGuide.com; website, the leading online platform that helps dispensaries treat patients affected by cancer.
→ 5,600 requests for medical information from healthcare professionals handled by our teams.

Employee well-being

→ Our employee engagement score rose by 1 point compared to a 2022 (survey conducted with Microsoft Viva Glint across 42 countries).
→ Ranked among the “World’s Best Employers” by Forbes magazine for the 3rd year running.
→ Accident rate (with time off): 4.46.
→ 300 employees took part in colorectal and skin cancer prevention workshops.
→ 1,500 employees were involved in humanitarian or environmental projects.

Environmental performance

→ Co-creation of the Green Impact Index Consortium to inform consumers about the social and environmental impact of products*.
→ 26% reduction in greenhouse gas emissions in scopes 1 and 2 (vs 2015) — 21% reduction in energy consumption in France** (vs 2015).
→ 30% reduction in water consumption in France** (vs 2018).
→ 90% of plant-based active ingredients extracted without solvents or using green solvents.
→ CSR policy assessed as “Outstanding” by AFNOR Certification***.

*Cosmetic and family health products (AFNOR Spec 2215)
** Industrial and tertiary sites
***Responsibility Europe label (ISO 26 000 standard)

Solidarity at regional level

→ 49 associations funded in Occitanie and products donated to 330 local structures.
→ Founding member of Cœur des Entreprises, an endowment fund bringing together 15 companies committed to fighting poverty in the greater Toulouse region.
→ Leading partner of Castres and Lavaur rugby clubs.
→ 11 local athletes supported as they trained for international competitions.
→ 15 local projects geared to protecting biodiversity supported in 10 countries by Klorane Botanical Foundation.

Fondation Pierre Fabre

→ €20 million spending commitments in 2023, of which 61% concerned Africa.
→ 35 ongoing programs to provide access to healthcare in 21 countries.
→ 49 scholarship students supported in Asia and Africa, including 10 doctoral students.